Cochrane · systematic review · CD009427
Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis
Xiao, Y, Wang, J, Luo, H · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
Multiple Sclerosis and Rare Diseases of the CNSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 40%Very low 0 · 0%Low 2 · 40%Moderate 1 · 20%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Sildenafil versus placebo for erectile dysfunction in patients with multiple sclerosis
Population: patients with erectile dysfunction in patients with multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
International Index of Erectile Function questionnaire 31 Sildenafil vs placebo | no estimate extracted | 2 studies · 420 participants | Ungraded |
International Index of Erectile Function questionnaire 41 Sildenafil vs placebo | no estimate extracted | 2 studies · 420 participants | Ungraded |
Sexual Encounter Profile questions 2 Sildenafil vs placebo | RR 1.28 [0.92, 1.78] | 1 study · 184 participants | Low Downgraded: risk of bias, imprecision |
Sexual Encounter Profile questions 3 Sildenafil vs placebo | RR 1.38 [1, 1.9] | 1 study · 187 participants | Low Downgraded: risk of bias, imprecision |
Global Assessment Question Sildenafil vs placebo | RR 2.72 [1.4, 5.28] | 2 studies · 406 participants | Moderate Downgraded: risk of bias |